Please login to the form below

MK-3475

This page shows the latest MK-3475 news and features for those working in and with pharma, biotech and healthcare.

be taken up by immune checkpoint inhibitors - BMS' nivolumab and Merck &Co's pembrolizumab (MK-3475) - which are currently in late-stage testing.

Merck could win anti-PD1 therapy race in Europe

Pembrolizumab (formerly lambrolizumab; MK-3475) is one of the highlights of Merck's R&D pipeline and is being evaluated across more than 30 types of cancer, with peak sales estimated
ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab. New data on Merck &Co's recently-filed anti-PD1 drug pembrolizumab (MK-3475) suggest the drug could be a 'paradigm shift'
AZ starts pivotal trials of lung cancer immunotherapy

Meanwhile, Merck &Co's MK-3475 - filed for melanoma earlier this year - and Bristol-Myers Squibb's nivolumab for NSCLC are targeting a related receptor called PD1.
FDA grants priority review to Merck’s cancer antibody

The latest news from the FDA continues to back this belief and puts MK-3475 on course to be the first anti-PD-1 antibody approved in the US. . ... Merck has also signed agreements with rivals Pfizer, Amgen and Incyte to test MK-3475 in combination with
Novartis enters PD-1 race via CoStim acquisition

Of these Merck appears to be in the lead, as it has filed a rolling marketing submission for its MK-3475. ... therapies seems backed up by Merck's recent announcement of a series of collaborations on MK-3475 with other drugmakers.

More from news
Approximately 7 fully matching, plus 8 partially matching documents found.

Interview: Bruno Strigini, MSD

Here among the products he points to are the company's anti-PD-1 immunotherapy MK-3475, for which a rolling approval was filed earlier this year as a second-line
Pharma deals during February 2014

Merck &Co also signed three separate agreements with Amgen, Incyte and Pfizer to investigate combination regimes with its experimental anti-PD-1 immunotherapy, MK-3475 (see Box 1). MK-3475 was

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Bruno Strigini leaves Merck & Co for Novartis

Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Add my company

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...